Rhythmic Metabolism in Osteosarcopenia: Emerging Evidence, a Chronometabolomic Framework for the Bone-Muscle Unit, and Research Priorities.
Key claim: A narrative review argues that time-anchored metabolomic profiling (chronometabolomics) is an emerging research framework for osteosarcopenia, with only scarce direct human evidence that disrupted metabolic rhythms affect the bone–muscle unit, and lists light, sleep regularization, protein distribution, time-restricted eating, and exercise or medication timing as candidates for trials rather than clinical recommendations.
Abstract
Osteosarcopenia combines low bone mass or skeletal fragility with sarcopenia, yet its metabolic biology is commonly assessed using single-time-point measurements. We conducted a structured narrative review of PubMed/MEDLINE, Web of Science Core Collection, Embase and Scopus from inception through 28 June 2026, supplemented by ScienceDirect, Google Scholar and citation chaining. Evidence was classified as direct human osteosarcopenia evidence, indirect human evidence, preclinical evidence or conceptual inference. Here, chronometabolomics denotes time-anchored or repeated metabolomic profiling used to estimate variation in phase, amplitude and pathway coordination in relation to sleep, feeding, activity and endocrine timing. Direct human evidence remains scarce. Component-specific human studies and experimental models suggest, but do not establish, that aging, chronic disease and irregular schedules may alter glucose-insulin, amino-acid, lipid, mitochondrial, redox-inflammatory, mineral-endocrine and microbial rhythms relevant to the bone-muscle unit. Chronometabolomics is therefore an emerging research framework, not a validated diagnostic or therapeutic approach. Daytime light, sleep regularization, protein distribution, time-restricted eating, exercise timing and medication timing remain candidates for controlled trials rather than current clinical recommendations; safety evaluation must address frailty, low body mass index, malnutrition, kidney disease, diabetes, polypharmacy, falls and inadequate protein or calcium intake.
Why this matters
Metabolomic aging signatures are typically sampled as single time points, ignoring circadian structure that may itself be an aging phenotype; a chronometabolomic framing would change how omics clocks for musculoskeletal aging are constructed and validated. The review is a research agenda, not evidence — it flags the bone–muscle unit as a candidate domain where rhythm-aware sampling could matter, but does not yet show that disrupted metabolic rhythms predict osteosarcopenia outcomes or that restoring them moves any clock.